Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells

European Journal of Pharmacology

Volumn 542, Issue 1-3, 2006, Pages 8-15

  Trog, Daniela ^a   Yeghiazaryan, Kristina ^a   Fountoulakis, Michael ^b   Friedlein, Arno ^b   Moenkemann, Heike ^a   Haertel, Nicolai ^c   Schueller, Heinrich ^a   Breipohl, Winrich ^a   Schild, Hans ^a   Leppert, David ^d   Golubnitschaja, Olga ^a  

^a UNIVERSITY OF BONN   (Germany)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Neurology and Gastroenterology   (United Kingdom)

Author keywords

Irradiation; Malignant glioma treatment; Metalloproteinases; Proteomics; Temozolomide; Tissue remodelling; Tumour invasiveness

Indexed keywords

GELATINASE; GELATINASE A; GELATINASE B; LYSOZYME; LYSOZYME C; MATRIX METALLOPROTEINASE 14; METALLOPROTEINASE; PROTEIN P53; SCLEROPROTEIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; GENETIC REGULATION; GLIOBLASTOMA; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IRRADIATION; MASS SPECTROMETRY; MOLECULAR BIOLOGY; MORPHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DACARBAZINE; GLIOMA; HUMANS; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UP-REGULATION;

EID: 33745999747     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.05.026     Document Type: Article

References (37)

1. Aizencang G., Harari P., Buldain G., Guerra L., Pickart M., Hernandez P., and Frydman B. Antiproliferative effects of N1,N4-dibenzylputrescine in human and rodent tumour cells. Cell. Mol. Biol. 44 (1998) 615-625
2. Arab S., Rutka J., and Lingwood C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol. Res. 11 (1999) 33-39
3. Benjamin R.S., Chawla S.P., Ewer M.S., Carrasco C.H., Mackay B., and Holmes F. Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update. Invest. New Drugs 3 (1985) 117-121
4. Bower M., Newlands E.S., Bleehen N.M., Brada M., Begent R.J., Calvert H., Colquhoun I., Lewis P., and Brampton M.H. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol. 40 (1997) 484-488
5. Burger P.C., Vogel F.S., Green S.B., and Strike T.A. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56 (1985) 1106-1111
6. Coleman D.J., Silverman R.H., Iwamoto T., Lizzi F.L., Rondeau M.J., Driller J., Rosado A., Abramson D.H., and Ellsworth R.M. Histopathologic effects of ultrasonically induced hyperthermia in intraocular malignant melanoma. Ophthalmology 95 (1988) 970-981
7. Cordes N., and Meineke V. Cell adhesion-mediated radioresistance (CAM-RR). Extracellular matrix-dependent improvement of cell survival in human tumour and normal cells in vitro. Strahlenther. Onkol. 179 (2003) 337-344
8. Cordes N., and van Beuningen D. Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro. Br. J. Cancer 88 (2003) 1470-1479
9. Cordes N., Hansmeier B., Beinke C., Meineke V., and van Beuningen D. Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br. J. Cancer 89 (2003) 2122-2132
10. Denny B.J., Wheelhouse R.T., Stevens M.F., Tsang L.L., and Slack J.A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33 (1994) 9045-9051
11. Efferth T., Ramirez T., Gebhart E., and Halatsch M.E. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem. Pharmacol. 67 (2004) 1689-1700
12. Fuks Z., Vlodavsky I., Andreeff M., McLoughlin M., and Haimovitz-Friedman A. Effects of extracellular matrix on the response of endothelial cells to radiation in vitro. Eur. J. Cancer 28 (1992) 725-731
13. Girolamo F., Virgintino D., Errede M., Capobianco C., Bernardini N., Bertossi M., and Roncali L. Involvement of metalloprotease-2 in the development of human brain microvessels. Histochem. Cell Biol. 122 (2004) 261-270
14. Goldshmidt O., Nadav L., Aingorn H., Irit C., Feinstein N., Ilan N., Zamir E., Geiger B., Vlodavsky I., and Katz B.Z. Human heparanase is localized within lysosomes in a stable form. Exp. Cell Res. 281 (2002) 50-62
15. Hazlehurst L.A., Valkov N., Wisner L., Storey J.A., Boulware D., Sullivan D.M., and Dalton W.S. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98 (2001) 1897-1903
16. Hegedus B., Zach J., Czirok A., Lovey J., and Vicsek T. Irradiation and Taxol treatment result in non-monotonous, dose-dependent changes in the motility of glioblastoma cells. J. Neuro-oncol. 67 (2004) 147-157
17. Horiguchi H., Sano T., and Hirose T. TP53 deleted cells in de novo glioblastomas using fluorescence in situ hybridization. Pathol. Int. 51 (2001) 187-192
18. Hosotani R., Miyamoto Y., Fujimoto K., Doi R., Otaka A., Fujii N., and Imamura M. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice. Clin. Cancer Res. 8 (2002) 1271-1276
19. Lakka S.S., Jasti S.L., Gondi C., Boyd D., Chandrasekar N., Dinh D.H., Olivero W.C., Gujrati M., and Rao J.S. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21 (2002) 5601-5608
20. Lamszus K., Kunkel P., and Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir., Suppl. 88 (2003) 169-177
21. Levicar N., Nuttall R.K., and Lah T.T. Proteases in brain tumour progression. Acta Neurochir. (Wien) 145 (2003) 825-838
22. Liekens S., De Clercq E., and Neyts J. Angiogenesis: regulators and clinical applications. Biochem. Pharmacol. 61 (2001) 253-270
23. Ma J., Murphy M., O'Dwyer P.J., Berman E., Reed K., and Gallo J.M. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem. Pharmacol. 63 (2002) 1219-1228
24. Naumann U., Wischhusen J., Weit S., Rieger J., Wolburg H., Massing U., and Weller M. Alkylphosphocholine-induced glioma cell death is BCL-X(L)-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation. Cell Death Differ. 11 (2004) 1326-1341
25. Notter M.F., and Kendig J.W. Differential sensitivity of neural cells to bilirubin toxicity. Exp. Neurol. 94 (1986) 670-682
26. Osoba D., Brada M., Yung W.K., and Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 18 (2000) 1481-1491
27. Paulsen F., Hoffmann W., Becker G., Belka C., Weinmann M., Classen J., Kortmann R.D., and Bamberg M. Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. J. Cancer Res. Clin. Oncol. 125 (1999) 411-418
28. Porro G., Bertolini G., Bonardi M.A., Giovanetti E., Lento P., Leoni F., Modena D., Pavich G., and Marcucci F. Diaminic carbonates, a new class of anti-inflammatory compounds: their biological characterization and mode of action. J. Pharmacol. Exp. Ther. 285 (1998) 193-200
29. Sallinen S.L., Sallinen P.K., Haapasalo H.K., Helin H.J., Helen P.T., Schraml P., Kallioniemi O.P., and Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 60 (2000) 6617-6622
30. Seifert H.W., Klingmulller G., and Tschubel K. Multivesicular vacuolization in malignant histiocytoma of the skin. Arch. Dermatol. Res. 261 (1978) 163-173
31. Trog D., Moenkemann H., Haertel N., Schueller H., and Golubnitschaja O. Expression of ABC-1 transporter is elevated in human glioma cells under irradiation and temozolomide treatment. Amino Acids 28 (2005) 213-219
32. Trog D., Fountoulakis M., Friedlein A., and Golubnitschaja O. Is current therapy of malignant gliomas beneficial for patients? Proteomics evidence of shifts in glioma cells expression patterns under clinically relevant treatment conditions. Proteomics 6 (2006) 2924-2930
33. 6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br. J. Cancer 73 (1996) 1049-1052
34. Wick W., Wild-Bode C., Frank B., and Weller M. BCL-2-induced glioma cell invasiveness depends on furin-like proteases. J. Neurochem. 91 (2004) 1275-1283
35. Wild-Bode C., Weller M., Rimner A., Dichgans J., and Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 61 (2001) 2744-2750
36. Wilm M., and Mann M. Analytical properties of the nanoelectrospray ion source. Anal. Chem. 68 (1996) 1-8
37. Yung W.K., Prados M.D., Yaya-Tur R., Rosenfeld S.S., Brada M., Friedman H.S., Albright R., Olson J., Chang S.M., O'Neill A.M., Friedman A.H., Bruner J., Yue N., Dugan M., Zaknoen S., and Levin V.A. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17 (1999) 2762-2771